Zepbound vs Mounjaro: What's the Difference?
Zepbound and Mounjaro both contain tirzepatide — so what's the difference? This guide explains FDA approvals, doses, pricing, and which to choose for weight loss.
More on Tirzepatide Options
How Tirzepatide Works
The science behind tirzepatide's dual GIP/GLP-1 mechanism.
Tirzepatide Side Effects Management
How to manage the most common side effects.
Ozempic vs Mounjaro
Full brand-name comparison of the two leading GLP-1 drugs.
Best Weight Loss Medication 2026
Where tirzepatide ranks among all weight loss drugs.
Same Drug, Two Brand Names
The short answer to "what's the difference between Zepbound and Mounjaro?" is: the FDA indication and the branding. Both contain tirzepatide — a dual GIP and GLP-1 receptor agonist developed by Eli Lilly — at identical doses, with the same mechanism of action, the same clinical efficacy, and the same side effect profile.
The distinction matters primarily for insurance coverage and prescribing context. Mounjaro was approved by the FDA in May 2022 for type 2 diabetes management. Zepbound was approved in November 2023 specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related health condition.
For a broader comparison of tirzepatide and semaglutide — the two dominant GLP-1 classes — see our semaglutide vs tirzepatide guide.
Side-by-Side Comparison
| Feature | Zepbound | Mounjaro |
|---|---|---|
| Active Ingredient | Tirzepatide | Tirzepatide |
| FDA Approval | Obesity / Weight Management | Type 2 Diabetes |
| Approval Date | November 2023 | May 2022 |
| Available Doses | 2.5, 5, 7.5, 10, 12.5, 15mg | 2.5, 5, 7.5, 10, 12.5, 15mg |
| Avg. Weight Loss | 20–22% (SURMOUNT-1) | 15–22% (SURPASS trials) |
| Dosing | Once weekly injection | Once weekly injection |
| Insurance Coverage | Obesity benefit (where exists) | Diabetes benefit |
| List Price/month | ~$1,059–$1,300 | ~$1,000–$1,300 |
| Compounded Version | Available (tirzepatide) | Available (tirzepatide) |
Cost and Insurance Differences
The list prices of Zepbound and Mounjaro are similar, but your out-of-pocket cost may differ significantly depending on your insurance coverage. This is where the approval indication matters most:
- Diabetes insurance plans: Mounjaro is covered when prescribed for T2D. If you have type 2 diabetes and a plan with diabetes coverage, Mounjaro may be $0–$25/month with savings programs or with insurance.
- Obesity benefit plans: Zepbound is covered under obesity management benefits — increasingly included in employer plans following the SELECT trial. Where this benefit exists, Zepbound copays can be as low as $25/month.
- No coverage: Both run $1,000–$1,300/month at list price. In this case, compounded tirzepatide through a program like Trimi reduces costs to $250–$450/month for the same active ingredient.
For a detailed cost analysis including all options, see our compounded tirzepatide cost guide.
Titration and Dosing — Identical Schedules
Whether you're prescribed Zepbound or Mounjaro, the dosing schedule is the same:
Tirzepatide Dose Escalation Schedule
The titration can be slowed at any step if GI side effects are problematic. Many patients find their optimal maintenance dose between 10mg and 15mg. For comprehensive side effect management, see our tirzepatide side effects guide.
Clinical Evidence: SURMOUNT vs SURPASS Trials
Zepbound's weight loss approval was supported by the SURMOUNT trials, which studied tirzepatide specifically in patients with obesity (without diabetes). SURMOUNT-1 showed 22.5% average weight loss at 15mg over 72 weeks. SURMOUNT-2 studied patients with obesity and type 2 diabetes, showing 15.7% weight loss.
Mounjaro's diabetes approval was based on the SURPASS trials, which included participants with type 2 diabetes. These trials showed significant HbA1c reduction alongside meaningful weight loss (up to 11.2kg on 15mg). The cardiovascular outcomes study SURPASS-CVOT added CV safety data.
Together, these trial programs make tirzepatide (in either brand form) the most evidence-backed GLP-1 medication for combined weight loss and metabolic health improvement available in 2026.
Choose Zepbound If:
- • Your primary goal is weight loss
- • You don't have type 2 diabetes
- • Your insurance has an obesity benefit
- • You want the specific obesity approval on your chart
Choose Mounjaro If:
- • You have type 2 diabetes
- • Your insurance covers diabetes drugs better
- • Your provider prefers the diabetes approval pathway
- • Zepbound is out of stock at your pharmacy
Full Side-by-Side Specification Table
The following table consolidates the regulatory, dosing, and access differences between Zepbound, Mounjaro, and a compounded tirzepatide alternative. Both branded products are manufactured by Eli Lilly and contain identical molecules; the meaningful differences sit in approval indication, insurance pathway, and price.
| Attribute | Zepbound | Mounjaro | Compounded Tirzepatide (Trimi) |
|---|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide | Tirzepatide |
| FDA-approved indication | Chronic weight management | Type 2 diabetes | Active ingredient is FDA-approved in commercial Mounjaro/Zepbound; the compounded preparation is not FDA-approved as a drug |
| FDA approval date | November 2023 | May 2022 | N/A — prepared per individual prescription |
| Manufacturer | Eli Lilly | Eli Lilly | 503A sterile compounding pharmacy (VialsRx — Texas State Board of Pharmacy #35264 — and GreenwichRx) |
| Available doses | 2.5, 5, 7.5, 10, 12.5, 15 mg | 2.5, 5, 7.5, 10, 12.5, 15 mg | Titrated per prescription, typically matching the FDA schedule |
| Form factor | Pre-filled auto-injector pen | Pre-filled auto-injector pen | Multi-dose vial with separate syringe |
| Average list price / month | ~$1,059 | ~$1,069 | $125 on annual plan |
| Insurance coverage profile | Weight-management plans where the obesity benefit exists | Type 2 diabetes plans | Cash-pay; not billed through insurance |
| Trimi alternative | N/A | N/A | $125/mo on annual plan, telehealth-prescribed |
Standard Dose Titration Schedule (Identical for Both Brands)
Per FDA prescribing information, tirzepatide titration starts at 2.5 mg once weekly and climbs by 2.5 mg every four weeks until a tolerable maintenance dose is reached. Most patients land between 10 mg and 15 mg. Clinical trials show that slower titration improves GI tolerance without compromising long-term outcomes.
| Phase | Weeks | Weekly dose | Notes |
|---|---|---|---|
| Initiation | Weeks 1–4 | 2.5 mg | Tolerance dose; not therapeutic for weight loss |
| Step 1 | Weeks 5–8 | 5 mg | First therapeutic dose |
| Step 2 | Weeks 9–12 | 7.5 mg | Optional intermediate step |
| Step 3 | Weeks 13–16 | 10 mg | Common maintenance dose |
| Step 4 | Weeks 17–20 | 12.5 mg | Optional intermediate step |
| Maximum | Weeks 21+ | 15 mg | Maximum FDA-labeled dose |
Results vary based on starting weight, dose tolerated, adherence, diet, and exercise. Your licensed clinician may prescribe off-label at their clinical discretion based on your individual case if a non-standard titration is appropriate.
Which to Ask Your Clinician For — Decision Tree
Because the molecule is identical, the right question is rarely "which works better" but "which gives me the best access path." Walk this tree top to bottom:
- Do you have a confirmed type 2 diabetes diagnosis (HbA1c ≥6.5)?
- Yes → Mounjaro is typically better-covered. Diabetes formularies include it; Lilly's diabetes savings card commonly applies.
- Is your focus chronic weight management without a T2D diagnosis (BMI ≥30, or ≥27 with a weight-related comorbidity)?
- Yes → Zepbound carries the specific obesity indication. If your employer plan has an obesity benefit, this is the prescription that triggers coverage.
- No insurance, brand inaccessible, on a waitlist, or paying cash?
- Yes → Compounded tirzepatide via a 503A pharmacy (e.g., the Trimi program at $125/mo on annual) keeps you on the same active ingredient at a fraction of branded retail. The compounded preparation is not FDA-approved as a drug; the active ingredient is FDA-approved in commercial Mounjaro and Zepbound.
This is general information, not medical advice. Consult a licensed clinician about which path fits your medical history.
Clinical Evidence: SURMOUNT and SURPASS Trial Programs
According to SURMOUNT-1 (Jastreboff et al., NEJM 2022, n=2,539), tirzepatide 15 mg produced a mean body-weight reduction of approximately 22.5 percent at 72 weeks in adults with obesity and without type 2 diabetes. The 5 mg arm produced approximately 15 percent reduction; placebo produced approximately 2.4 percent. This trial is the pivotal evidence underlying Zepbound's FDA approval.
"In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight."
The SURPASS program supported Mounjaro's diabetes approval. SURPASS-2 (Frias et al., NEJM 2021) compared tirzepatide to semaglutide 1 mg in patients with type 2 diabetes. Per FDA prescribing information for Mounjaro, the trial reported HbA1c reductions up to 2.30 percentage points on tirzepatide 15 mg versus 1.86 on semaglutide, alongside weight reductions of up to 11.2 kg on 15 mg.
Clinical trials show that the molecule's dual GIP and GLP-1 receptor agonism is the mechanism behind these outcomes — mechanism is identical between Zepbound and Mounjaro because the molecule is identical. For mechanism detail see our how tirzepatide works primer.
Per Jastreboff AM et al., NEJM 2022;387(3):205–216; Frias JP et al., NEJM 2021;385(6):503–515; FDA prescribing information for Zepbound (2023) and Mounjaro (2022).What About Compounded Tirzepatide?
Compounded tirzepatide contains the same active ingredient as Zepbound and Mounjaro. It is prepared by a state-licensed 503A community sterile compounding pharmacy per an individual prescription written by a licensed clinician. The Trimi program partners with VialsRx (Texas State Board of Pharmacy license #35264) and GreenwichRx for compounding fulfillment.
A clear regulatory framing matters here: compounded tirzepatide is not FDA-approved as a drug. The active ingredient (tirzepatide) is FDA-approved in commercial Mounjaro and Zepbound. Compounded preparations are governed by FDA's 503A pathway and state boards of pharmacy, not by an NDA approval. Your licensed clinician may prescribe off-label at their clinical discretion based on your individual case.
The practical difference is price. Zepbound retails at approximately $1,059 per month at list price; the Trimi compounded tirzepatide program is $125 per month on an annual plan — same active ingredient, dramatically different out-of-pocket exposure. For the full pricing landscape across every legal access route, read our cheapest legal GLP-1 online 2026 cornerstone, which maps the comprehensive 2026 cheapest legal GLP-1 online guide across branded, savings-card, and compounded paths.
Results vary based on starting weight, dose tolerated, adherence, diet, and exercise.
Tirzepatide Risk Acknowledgment
Tirzepatide carries side-effect and warning profiles that apply equally to Zepbound, Mounjaro, and compounded tirzepatide because they share the same molecule.
- Common side effects per FDA prescribing information: nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, injection-site reactions.
- Gallbladder disease: cholelithiasis and acute cholecystitis have been reported with rapid weight loss on GLP-1 therapy.
- Pancreatitis: acute pancreatitis has been reported. Discontinue if suspected and evaluate.
- FDA boxed warning — thyroid C-cell tumors: in rodent studies tirzepatide caused thyroid C-cell tumors. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Acute kidney injury: severe gastrointestinal adverse reactions can lead to dehydration and acute kidney injury, especially in patients with pre-existing renal impairment.
- Hypoglycemia: risk is increased when used with insulin or insulin secretagogues; dose adjustment of those agents may be required.
This is general information, not medical advice. Consult a licensed clinician.
Per FDA prescribing information for Zepbound (tirzepatide), Eli Lilly, 2023; FDA prescribing information for Mounjaro, 2022.Frequently Asked Questions
Are Zepbound and Mounjaro the same drug?
Yes. Both Zepbound and Mounjaro contain the same active ingredient — tirzepatide — at the same doses. The difference is FDA approval: Mounjaro is approved for type 2 diabetes management, while Zepbound is approved specifically for chronic weight management in adults with obesity or overweight with weight-related conditions.
Can Mounjaro be used for weight loss?
Yes, Mounjaro can be and frequently is prescribed off-label for weight loss. Before Zepbound's approval in November 2023, Mounjaro was the only branded tirzepatide option. Many patients and providers continue to use Mounjaro off-label for obesity when Zepbound is unavailable or when a patient has diabetes.
Is Zepbound cheaper than Mounjaro?
The list prices are similar (~$1,000–$1,300/month), but Zepbound's pricing strategy has sometimes offered savings vials (single-dose vials at lower cost) compared to Mounjaro's auto-injector pens. Insurance coverage differs: Mounjaro may be covered by diabetes-focused plans while Zepbound falls under obesity/weight management benefits.
What doses do Zepbound and Mounjaro come in?
Both come in the same dose strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg weekly injections. The titration schedule is identical: start at 2.5mg, increase by 2.5mg every 4 weeks as tolerated, with a maintenance dose typically at 10mg, 12.5mg, or 15mg.
Which should I ask for — Zepbound or Mounjaro?
If your primary goal is weight loss and you don't have type 2 diabetes, ask for Zepbound — it has the specific obesity approval and may have different insurance coverage or savings programs. If you have type 2 diabetes, either works but Mounjaro may be better covered by diabetes-focused insurance plans.
Can I switch from Mounjaro to Zepbound?
Yes. Because Mounjaro and Zepbound contain the same active ingredient (tirzepatide) at identical doses, transitioning is typically a one-to-one switch at the same dose. Your licensed clinician may prescribe off-label at their clinical discretion based on your individual case. Insurance benefits drive most switches: a patient on Mounjaro for off-label weight loss may move to Zepbound once an obesity benefit kicks in, since coverage is determined by the FDA-approved indication on the prescription, not the molecule itself.
Does insurance cover Zepbound for weight loss?
Coverage is expanding but inconsistent. Per the Kaiser Family Foundation's 2024 employer benefits survey, roughly 18 percent of large employers covered GLP-1s for obesity, up from prior years following the SELECT cardiovascular outcomes trial. Medicare Part D does not cover Zepbound for weight loss alone under current rules, though it covers GLP-1s when prescribed for type 2 diabetes or specific cardiovascular indications. Check your plan's formulary for a specific obesity benefit and any prior-authorization requirements (typically BMI ≥30, or BMI ≥27 with a comorbidity).
What's the difference between Zepbound and compounded tirzepatide?
Zepbound is the FDA-approved branded tirzepatide product manufactured by Eli Lilly in pre-filled auto-injector pens. Compounded tirzepatide is prepared by a state-licensed 503A sterile compounding pharmacy per individual prescription. The active ingredient (tirzepatide) is FDA-approved in commercial Zepbound and Mounjaro; the compounded preparation itself is not FDA-approved as a drug. Pricing is the largest practical difference: Zepbound runs roughly $1,059 per month at retail, while compounded tirzepatide through a telehealth program like Trimi is $125 per month on an annual plan. Results vary based on starting weight, dose tolerated, adherence, diet, and exercise.
How much weight loss can I expect on Zepbound vs Mounjaro?
Per FDA prescribing information for Zepbound and the SURMOUNT-1 trial published in NEJM in 2022, participants on the 15mg dose lost approximately 22.5 percent of body weight over 72 weeks. SURPASS trials in patients with type 2 diabetes (the Mounjaro indication) showed weight reductions up to 11.2 kg on 15mg alongside HbA1c improvements. Because the molecule is identical, the weight-loss potential is also functionally identical at matched doses; trial-population differences (BMI, baseline HbA1c) explain most of the headline-number gap. Results vary based on starting weight, dose tolerated, adherence, diet, and exercise.
Are Zepbound and Mounjaro the same as Ozempic and Wegovy?
No. Zepbound and Mounjaro contain tirzepatide, a dual GIP and GLP-1 receptor agonist. Ozempic and Wegovy contain semaglutide, a single-pathway GLP-1 receptor agonist. Per the SURPASS-2 head-to-head trial (NEJM 2021), tirzepatide produced greater HbA1c reduction and weight loss than semaglutide at matched comparator doses. The brand pairing mirrors Lilly's vs. Novo Nordisk's regulatory strategy: Mounjaro/Ozempic carry the diabetes indication, Zepbound/Wegovy carry the chronic-weight-management indication. See our semaglutide vs tirzepatide guide for the molecule-level comparison.
Sources & References
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." NEJM. 2022;387(3):205–216.
- Garvey WT, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)." Lancet. 2023;402(10402):613–626.
- Frias JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)." NEJM. 2021;385(6):503–515.
- FDA. "FDA Approves New Medication for Chronic Weight Management." FDA.gov. November 8, 2023.